FASEB J. Thermo Fisher Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fang, J.
Right arrow Articles by Jiang, B.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, J.
Right arrow Articles by Jiang, B.-H.
(The FASEB Journal. 2005;19:342-353.)
© 2005 FASEB

Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways

Jing Fang, Chang Xia, Zongxian Cao, Jenny Z. Zheng, Eddie Reed and Bing-Hua Jiang1

The Mary Babb Randolph Cancer Center, Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, West Virginia, USA

1Correspondence: MBR Cancer Center, Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV 26506-9300, USA. E-mail: bhjiang{at}hsc.wvu.edu

Apigenin is a nontoxic dietary flavonoid that has been shown to possess anti-tumor properties and therefore poses special interest for the development of a novel chemopreventive and/or chemotherapeutic agent for cancer. Ovarian cancer is one of the most common causes of cancer death among women. Here we demonstrate that apigenin inhibits expression of vascular endothelial growth factor (VEGF) in human ovarian cancer cells. VEGF plays an important role in tumor angiogenesis and growth. We found that apigenin inhibited VEGF expression at the transcriptional level through expression of hypoxia-inducible factor 1{alpha} (HIF-1{alpha}). Apigenin inhibited expression of HIF-1{alpha} and VEGF via the PI3K/AKT/p70S6K1 and HDM2/p53 pathways. Apigenin inhibited tube formation in vitro by endothelial cells. These findings reveal a novel role of apigenin in inhibiting HIF-1 and VEGF expression that is important for tumor angiogenesis and growth, identifying new signaling molecules that mediate this regulation.—Fang, J., Xia, C., Cao, Z., Zheng, J. Z., Reed, E., Jiang, B.-H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways.


Key Words: vascular endothelial growth factor • ovarian cancer • hypoxia inducible factor 1 • tumor growth • HUVEC




This article has been cited by other articles:


Home page
Cancer Res.Home page
V. A. Carroll and M. Ashcroft
Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma
Cancer Res., January 15, 2008; 68(2): 545 - 552.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Xia, Q. Meng, L.-Z. Liu, Y. Rojanasakul, X.-R. Wang, and B.-H. Jiang
Reactive Oxygen Species Regulate Angiogenesis and Tumor Growth through Vascular Endothelial Growth Factor
Cancer Res., November 15, 2007; 67(22): 10823 - 10830.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
M. Milkiewicz, J. L. Doyle, T. Fudalewski, E. Ispanovic, M. Aghasi, and T. L. Haas
HIF-1{alpha} and HIF-2{alpha} play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle
J. Physiol., September 1, 2007; 583(2): 753 - 766.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Albini, D. M. Noonan, and N. Ferrari
Molecular Pathways for Cancer Angioprevention
Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Shukla, G. T. MacLennan, C. A. Flask, P. Fu, A. Mishra, M. I. Resnick, and S. Gupta
Blockade of {beta}-Catenin Signaling by Plant Flavonoid Apigenin Suppresses Prostate Carcinogenesis in TRAMP Mice
Cancer Res., July 15, 2007; 67(14): 6925 - 6935.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. Fang, Q. Zhou, L.-Z. Liu, C. Xia, X. Hu, X. Shi, and B.-H. Jiang
Apigenin inhibits tumor angiogenesis through decreasing HIF-1{alpha} and VEGF expression
Carcinogenesis, April 1, 2007; 28(4): 858 - 864.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Li, Z. Zhang, D. L. Hill, H. Wang, and R. Zhang
Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway
Cancer Res., March 1, 2007; 67(5): 1988 - 1996.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. Fang, Q. Zhou, X.-l. Shi, and B.-h. Jiang
Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells
Carcinogenesis, March 1, 2007; 28(3): 713 - 723.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
Q. Zhou, L.-Z. Liu, B. Fu, X. Hu, X. Shi, J. Fang, and B.-H. Jiang
Reactive oxygen species regulate insulin-induced VEGF and HIF-1{alpha} expression through the activation of p70S6K1 in human prostate cancer cells
Carcinogenesis, January 1, 2007; 28(1): 28 - 37.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Fu, J. Xue, Z. Li, X. Shi, B.-H. Jiang, and J. Fang
Chrysin inhibits expression of hypoxia-inducible factor-1{alpha} through reducing hypoxia-inducible factor-1{alpha} stability and inhibiting its protein synthesis
Mol. Cancer Ther., January 1, 2007; 6(1): 220 - 226.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. Hubert, S. Paris, J.-P. Piret, N. Ninane, M. Raes, and C. Michiels
Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level
J. Cell Sci., August 15, 2006; 119(16): 3351 - 3362.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Shukla and S. Gupta
Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft.
Mol. Cancer Ther., April 1, 2006; 5(4): 843 - 852.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by The Federation of American Societies for Experimental Biology.